The size of the Clinical Nutrition market in Europe was worth USD 3.82 Billion in 2021 and is estimated to be growing at a CAGR of 7.17% and worth USD 5.39 Billion by 2026. The European clinical nutrition market is driven by the aging population and increased disease diagnosis.
The rising prevalence of metabolic disorders and excessive healthcare spending are two important drivers driving the European clinical nutrition market expansion. Over the last decade, the number of people diagnosed with metabolic diseases has increased, increasing the number of individuals diagnosed.
Dietary therapy is necessary for normal growth and development and to prevent acute and long-term effects of the disorder. In people with metabolic diseases, failing to follow a certain nutritional regimen can lead to problems and even death. Nutritional therapy is required for patients with hereditary metabolic abnormalities for the rest of their lives. Treating patients with various inborn metabolic necessitates a multidisciplinary strategy that includes both dietary and medical care.
The inability of the body to create non-essential molecules such as vitamins, amino acids, and several chemicals involved in metabolic pathways causes the majority of metabolic disorders. Most of these ailments can be treated with just one or two vitamin pills. All of these factors have a role in the market’s expansion.
The European clinical nutrition market is being held back by the necessity to meet nutritional therapy's safety and quality criteria. Pharmaceutical items include clinical nutritional supplements. The producers should adhere to Food and Drug Administration and European Medicines Agency’s recommendations. The challenges in obtaining permissions from government bodies are a significant challenge.
Impact of COVID-19 on the European Clinical Nutrition Market:
Infection with COVID-19 has become a serious public health concern, and clinical nutrition can help prevent infection and treat infection-related malnutrition. The European Society for Clinical Nutrition and Metabolism, for example, has published nutritional therapy guidelines for COVID-19 infected ICU patients. As a result, nutritional support plays a critical role in this context, assisting the segment’s growth.
This research report on the European clinical nutrition market has been segmented and sub-segmented into the following categories:
By Product Type:
By Therapeutic Areas:
By Ingredients Type:
By Country:
The Europe Clinical Nutrition Market is estimated to develop at a healthy growth rate over the forecast period. Excessive healthcare spending and the increased prevalence of metabolic illnesses are two major factors driving the market growth.
The German clinical nutrition market is expected to showcase a significant CAGR during the forecast period, from the large number of people suffering from chronic diseases, an aging population, and an increase in the incidence of metabolic disorders. The country also has a high prevalence of metabolic syndrome, characterized by anomalies such as hypertension, abdominal obesity, dyslipidemia, and raised blood glucose levels.
As individuals age older in Germany, the number of multimorbid patients is also rising. According to a survey conducted by Germany Health Update, the overall prevalence of multimorbid individuals is roughly 39%.
According to the Global Health and Wellness Survey, more than 70% of Germans aged 65 and over had a metabolic condition in the previous year. Furthermore, food therapy is an important aspect of treating many illnesses to minimize acute repercussions, such as metabolic decompensation and long-term complications.
The UK clinical nutrition market is another lucrative regional market in Europe to capture the growth possibilities for the market participants during the forecast period. In addition, countries such as France, Spain, and Italy are expected to have promising growth rates during the forecast period.
KEY MARKET PLAYERS:
Notable companies operating in the Europe Clinical Nutrition Market profiled in this report are Nestle Nutrition, Abbott Laboratories Inc., Gentiva Health Services Inc., Mead Johnson & Company, Kendall, Ajinomoto Co. Inc., Hospira Inc., Hero Nutritionals Inc., Lonza Ltd, Baxter International Inc., B. Braun Melsungen AG, H. J. Heinz Company, American Home Patient Inc. and Fresenius Kabi.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Route of Administration
5.1.1 Oral Nutrition
5.1.2 Enteral Nutrition
5.1.3 Parenteral Nutrition
5.2 By Therapeutic Area
5.2.1 Malabsorption
5.2.2 Diarrhoea
5.2.3 Cancer
5.2.4 Food Allergies
5.2.5 Maldigestion
5.2.6 Diabetes
5.2.7 Short-Bowel Syndrome
5.2.8 Acute Lung Injury
5.2.9 Acute Respiratory Distress
5.3 By Ingredients Type
5.3.1 Vitamins
5.3.2 Minerals
5.3.3 Carbohydrates
5.3.4 Amino Acids
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Nestle Nutrition
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Abbott Laboratories Inc.
8.3 Gentiva Health Services Inc.
8.4 Mead Johnson & Company
8.5 Kendall
8.6 Ajinomoto Co. Inc.
8.7 Hospira Inc.
8.8 Hero Nutritionals Inc.
8.9 Lonza Ltd
8.10 Baxter International Inc.
8.11 B. Braun Melsungen AG
8.12 H. J. Heinz Company
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
